OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
Last trade$1.63
Day change+$0.005 (+0.31%)
Day range$1.59 – $1.65
Volume1,776,853
Market cap$1.20B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.2B
Price / earnings
—
Price / book
1.08×
Price / sales
2.4×
EV / sales
2.57×
EV / EBITDA
-22.98×
Profitability
Earnings per share
-$0.20
Return on assets
-7.87%
Return on equity
-13.26%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.43×
Current ratio
5.27×
Quick ratio
4.94×
Cash ratio
2.55×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$135.34M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for OPK, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$65.41M
$163.58M
$124.2M
$148.45M
$56.43M
$156.81M
$149.95M
$183.64M
Cost of revenue
$23.35M
$83.56M
$78.44M
$84.43M
$21.37M
$107.41M
$107.33M
$98.98M
Gross profit
$42.06M
$80.02M
$45.76M
$64.03M
$35.05M
$49.4M
$42.62M
$84.66M
Selling, general and administrative
$24.84M
$52.92M
$48.61M
$50.52M
$22.27M
$59.6M
$59.09M
$67.03M
Research and development
$32.18M
$33.17M
$29.2M
$32.77M
$29.8M
$30.34M
$30.84M
$30.43M
Total operating expenses
$73.47M
$105.06M
$96.77M
$102.34M
$68.61M
$109.38M
$109.79M
$117.8M
Operating income
-$31.41M
-$25.04M
-$51.02M
-$38.32M
-$33.55M
-$59.98M
-$67.17M
-$33.14M
Interest expense
-$13.45M
-$11.38M
-$10.94M
-$11.31M
-$11.33M
-$70.33M
-$15.47M
-$14.24M
Income before taxes
-$37.87M
-$13.4M
-$60.96M
-$46.9M
-$40.97M
-$162.52M
-$73.38M
$34.98M
Income taxes
-$7.31M
-$4.98M
-$6.11M
-$15.66M
-$8.05M
-$14.08M
-$5.77M
$20.95M
Net income
-$53.53M
-$8.42M
-$54.85M
-$31.26M
$21.63M
-$148.44M
-$67.61M
$14.03M
Net income attributable to common shareholders
-$53.53M
-$8.42M
-$54.85M
-$31.26M
$21.63M
-$148.44M
-$67.61M
$14.03M
EBITDA
-$8.68M
-$2.63M
-$28.82M
-$15.94M
-$10.81M
-$36.95M
-$43.68M
-$9.1M
Basic earnings per share
-$0.07
-$0.01
-$0.07
-$0.04
$0.03
-$0.19
-$0.10
$0.02
Diluted earnings per share
-$0.07
-$0.01
-$0.07
-$0.04
$0.03
-$0.19
-$0.10
$0.04
Recent news
Company coverage with links to the original publishers.
Cocrystal Pharma announced completion of dosing in its Phase 1b challenge study for CDI-988, an oral antiviral candidate for norovirus prevention and treatment, with no serious adverse events reported. The company received a $5 million private placement investment from OPKO Health and appointed antiviral development expert Carol Brosgart, MD to its Board. Preliminary efficacy results are expected near the end of 2026.
Hims & Hers (HIMS) reported Q3 2026 EPS of 3 cents, missing estimates by 57.1%, though revenues grew 48.7% year-over-year to $890.4 million. The company faced margin compression due to lower-margin weight loss products and a sequential subscriber decline of 100,000. HIMS lowered its full-year adjusted EBITDA guidance to $257-$277 million but raised international revenue outlook to at least $650 million.
Rigetti Computing (RGTI) reported Q2 2026 adjusted loss per share of 6 cents with revenues declining 27.5% to $1.41 million, missing consensus estimates by 57.6%. Despite gross margin expansion to 60.7%, operating losses widened to $33.19 million due to increased R&D spending. The company targets $20 million in 2026 revenues and plans to develop a 300+ qubit quantum system by mid-2028.
Veeva Systems (VEEV) is well-positioned for growth driven by its diversified product portfolio, strong Q2 fiscal 2027 results, and accelerating Vault CRM adoption with over 180 customers live and 12 of top 20 biopharma commitments. However, market saturation in the life sciences CRM sector poses a headwind to future growth rates. The company raised its fiscal 2027 outlook and expects 35% growth over the next five years.
Becton, Dickinson and Company (BD) delivered better-than-expected Q4 fiscal 2026 results with adjusted EPS up 27.3% and revenues up 5.4%, driven by growth across all four business segments. However, the stock fell 6.4% in pre-market trading due to weak fiscal 2027 guidance projecting only low-single-digit revenue growth and adjusted EPS of $13.10-$13.30. Concerns also include sluggish Connected Care revenue growth and declining Medication Management Solutions sales.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.